CLAIMS:

1. Use of a humanized antibody or fragment thereof which binds to beta-amyloid in the preparation of a medicament for reducing the plaque load in the retinal ganglion cell layer of an animal suffering from cortical visual deficits, glaucoma, optic neuritis, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or fragment thereof comprises:

I. (A) (i) a heavy chain variable region (HCVR) comprising (a) a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and (ii) a light chain variable region (LCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 12; or

(B) (i) a light chain variable region (LCVR) comprising (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, or the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and (ii) a heavy chain variable region comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 15; and

II. a human IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

2. Use of a humanized antibody or fragment thereof which binds to beta-amyloid in the preparation of a medicament for reducing the amount of plaques in the retinal ganglion cell layer of an animal suffering from cortical visual deficits, glaucoma, optic neuritis, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or fragment thereof comprises:

I. (A) (i) a heavy chain variable region (HCVR) comprising (a) a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (c) a

CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and (ii) a light chain variable region comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 12; or

(B) (i) a light chain variable region (LCVR) comprising (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, or the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and (ii) a heavy chain variable region comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 15; and

II. a human IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

3. Use of a humanized antibody or fragment thereof which binds to beta-amyloid in the preparation of a medicament for decreasing the total amount of soluble beta-amyloid in the retinal ganglion cell layer of an animal suffering from cortical visual deficits, glaucoma, optic neuritis, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or functional fragment thereof comprises:

I. (A) (i) a heavy chain variable region (HCVR) comprising (a) a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and (ii) a light chain variable region comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 12; or

(B) (i) a light chain variable region (LCVR) comprising (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, or the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS, and (c) a CDR3 comprising the amino acid sequence of SEQ ID

NO: 6; and (ii) a heavy chain variable region comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 15; and

II. a human IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

4. The use according to any one of claims 1-3, wherein the humanized antibody or fragment thereof comprises a D265A mutation in the Fc region.

5. The use according to any one of claims 1-4, wherein the animal is a mammal.

6. The use according to claim 5, wherein the mammal is a human.

7. The use according to any one of claims 1-6, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 12 and the HCVR comprises the amino acid sequence of SEQ ID NO: 15.

8. The use according to any one of claims 1-6, wherein the CDR2 of the LCVR comprises the amino acid sequence of SEQ ID NO: 5.

9. The use according to any one of claims 1-6, wherein the CDR2 of the LCVR comprises the amino acid sequence RVSNRFS or the amino acid sequence KVSSRFS.

10. The use according to any one of claims 1-7, wherein the humanized antibody comprises the light chain of SEQ ID NO: 13.

11. The use according to any one of claims 1-6, wherein the humanized antibody or fragment thereof comprises:

(a) an LCVR comprising the amino acid Lys or Gln in Kabat position 45;

(b) an LCVR comprising the amino acid Phe or Tyr in Kabat position 87;

(c) an LCVR comprising the amino acid Lys or Arg in Kabat position 50;

(d) an LCVR comprising the amino acid Asn or Ser in Kabat position 53;

(e) an HCVR comprising the amino acid Ser in Kabat position 94; and/or

(f) an HCVR comprising the amino acid Leu in Kabat position 47.

12. The use according to any one of claims 1-11, wherein the animal suffers from glaucoma.

13. The use according to claim 12 wherein the glaucoma is selected from the group consisting of chronic open-angle glaucoma (COAG), acute angle closure glaucoma (AACG), mixed or combined mechanism glaucoma, normal tension glaucoma, congenital glaucoma, secondary glaucoma, pigmentary glaucoma, and exfoliative glaucoma.

14. The use according to any one of claims 1-11, wherein the animal suffers from cortical visual deficits, optic neuritis, or lattice dystrophy.

CLAIMS:

1. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for reducing the plaque load in the retinal ganglion cell layer of an animal suffering from cortical visual deficits, glaucoma, optic nerve drusen, optic neuritis, cataract, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a serine in Kabat position 94, and (e) a leucine in Kabat position 47; and

(ii) a light chain variable region (LCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

2. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for reducing the amount of plaques in the retinal ganglion cell layer of an animal suffering from cortical visual deficits, glaucoma, optic nerve drusen, optic neuritis, cataract, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of

SEQ ID NO: 2, (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a serine in Kabat position 94, and (e) a leucine in Kabat position 47; and

(ii) a light chain variable region (LCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

3. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for decreasing the total amount of soluble amyloid-β in the retinal ganglion cell layer of an animal suffering from cortical visual deficits, glaucoma, optic nerve drusen, optic neuritis, cataract, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a serine in Kabat position 94, and (e) a leucine in Kabat position 47; and

(ii) a light chain variable region (LCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238,

239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

4. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for preventing, treating or alleviating one or more effects of cortical visual deficits, glaucoma, optic nerve drusen, optic neuritis, cataract, ocular amyloidosis, or lattice dystrophy in an animal, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a serine in Kabat position 94, and (e) a leucine in Kabat position 47; and

(ii) a light chain variable region (LCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

5. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for retaining or decreasing ocular pressure in the eyes of an animal suffering from cortical visual deficits, glaucoma, optic nerve drusen, optic neuritis, cataract, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid

sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3, (d) a serine in Kabat position 94, and (e) a leucine in Kabat position 47; and

(ii) a light chain variable region (LCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

6. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for reducing the plaque load in the retinal ganglion cell layer of an animal suffering from an ocular disease associated with an amyloid-beta-related pathological abnormality or change in the tissues of the visual system provided that the ocular disease is not macular degeneration or optic neuropathy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) an LCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, the amino acid sequence RVSNRFS, or the amino acid sequence

KVSSRFS; and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and an HCVR comprising the amino acid sequence of SEQ ID NO: 15,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

7. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for reducing the amount of plaques in the retinal ganglion cell layer of an animal suffering from an ocular disease associated with an amyloid-beta-related pathological abnormality or change in the tissues of the visual system provided that the ocular disease is not macular degeneration or optic neuropathy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) an LCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS; and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and an HCVR comprising the amino acid sequence of SEQ ID NO: 15,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

8. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for decreasing the total amount of soluble amyloid-β in the retinal ganglion cell layer of an animal suffering from an ocular disease associated with an amyloid-beta-related pathological abnormality or change in the tissues of the visual system provided that the ocular disease is not macular degeneration or optic neuropathy, wherein the the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) an LCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS; and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and an HCVR comprising the amino acid sequence of SEQ ID NO: 15,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

9. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for preventing, treating or alleviating one or more effects of an ocular disease associated with an amyloid-beta-related pathological abnormality or change in the tissues of the visual system in an animal provided that the ocular disease is not macular degeneration or optic neuropathy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) an LCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS; and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and an HCVR comprising the amino acid sequence of SEQ ID NO: 15,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

10. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for retaining or decreasing ocular pressure in the eyes of an animal suffering from an ocular disease associated with an amyloid-beta-related pathological abnormality or change in the tissues of the visual system provided that the ocular disease is not macular degeneration or optic neuropathy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) an LCVR comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of

SEQ ID NO: 4; (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5, the amino acid sequence RVSNRFS, or the amino acid sequence KVSSRFS; and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and an HCVR comprising the amino acid sequence of SEQ ID NO: 15,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

11. Use of a humanized antibody or a functional fragment thereof which recognizes and binds to beta-amyloid protein in the preparation of a medicament for the treatment of cortical visual deficits, glaucoma, optic nerve drusen, optic neuritis, cataract, ocular amyloidosis, or lattice dystrophy, wherein the humanized antibody or functional fragment thereof comprises:

(i) a heavy chain variable region (HCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 1, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and

(ii) a light chain variable region (LCVR) comprising, integrated into human- or primate-derived framework regions: (a) a CDR1 comprising the amino acid sequence of SEQ ID NO: 4, (b) a CDR2 comprising the amino acid sequence of SEQ ID NO: 5 or the amino acid sequence of SEQ ID NO: 5 with one amino acid substitution; and (c) a CDR3 comprising the amino acid sequence of SEQ ID NO: 6,

wherein the humanized antibody or functional fragment thereof comprises an IgG1 Fc region which comprises an amino acid modification at any one or more of amino acid positions 238, 239, 248, 249, 252, 254, 265, 268, 269, 270, 272, 278, 289, 292, 293, 294, 295, 296, 298, 301, 303, 322, 324, 327, 329, 333, 335, 338, 340, 373, 376, 382, 388, 389, 414, 416, 419, 434, 435, 437, 438 or 439 of the IgG1 Fc region.

12. The use according to any one of claims 1-11, wherein the humanized antibody or functional fragment thereof comprises a D265A mutation in the Fc region.

13. The use according to any one of claims 1-12, wherein the animal is a mammal.

14. The use according to claim 13, wherein the mammal is a human.

15. The use according to any one of claims 1-14, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 12 and the HCVR comprises the amino acid sequence of SEQ ID NO: 15.

16. The use according to any one of claims 1-14, wherein the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 5.

17. The use according to any one of claims 1-14, wherein the light chain CDR2 comprises the amino acid sequence RVSNRFS or the amino acid sequence KVSSRFS.

18. The use according to any one of claims 7-10, wherein the ocular disease associated with an amyloid-beta-related pathological abnormality or change in the tissues of the visual system is glaucoma.

19. The use according to claim 18, wherein the glaucoma is selected from the group consisting of chronic open-angle glaucoma (COAG), acute angle closure glaucoma (AACG), mixed or combined mechanism glaucoma, normal tension glaucoma, congenital glaucoma, secondary glaucoma, pigmentary glaucoma, and exfoliative glaucoma.

20. The use according to any one of claims 1-19, wherein the humanized antibody comprises the light chain of SEQ ID NO: 13.

21. The use according to any one of claims 1-19, wherein the LCVR of the humanized antibody or active fragment thereof comprises the amino acid Lys or Gln in Kabat position 45; and/or the amino acid Phe or Tyr in Kabat position 87, and/or the amino acid Lys or Arg in Kabat position 50, and/or the amino acid Asn or Ser in Kabat position 53.